


## Doxorubicin-SMCC

Cat. No.:	HY-116063		
CAS No.:	400647-59-8		
Molecular Formula:	C <sub>39</sub> H <sub>42</sub> N <sub>2</sub> O <sub>14</sub>		
Molecular Weight:	762.76		
Target:	Drug-Linker Conjugates for ADC		
Pathway:	Antibody-drug Conjugate/ADC Related		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

In Vitro	DMSO : 62.5 mg/mL (81.94 mM; Need ultrasonic)			
		Solvent Concentration	Mass	
			1 mg	5 mg
	Preparing Stock Solutions		10 mg	
	1 mM	1.3110 mL	6.5551 mL	13.1103 mL
	5 mM	0.2622 mL	1.3110 mL	2.6221 mL
	10 mM	0.1311 mL	0.6555 mL	1.3110 mL
Please refer to the solubility information to select the appropriate solvent.				
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2.08 mg/mL (2.73 mM); Suspended solution; Need ultrasonic			
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.08 mg/mL (2.73 mM); Suspended solution; Need ultrasonic			

### BIOLOGICAL ACTIVITY

Description	Doxorubicin-SMCC is a agent-linker conjugate for ADC. Doxorubicin-SMCC contains a non-cleavable ADC linker and a DNA topoisomerase II inhibitor Doxorubicin <sup>[1]</sup> .
IC <sub>50</sub> & Target	Daunorubicins/Doxorubicins
In Vitro	ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## REFERENCES

---

[1]. Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017 May;16(5):315-337.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA